Lenvatinib Sandoz

Lenvatinib, the active ingredient in Lenvatinib Sandoz, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats differentiated thyroid carcinoma, renal cell carcinoma and hepatocellular carcinoma in adult patients.

GNH USA supplies Lenvatinib Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Lenvatinib is a tyrosine kinase inhibitor used in oncology to block angiogenesis and tumor growth.

- Differentiated thyroid carcinoma: improves progression‑free survival in patients with radioactive‑iodine‑refractory disease. - Renal cell carcinoma: reduces tumor burden and extends overall survival in advanced clear‑cell RCC. - Hepatocellular carcinoma: delays disease progression in patients with unresectable HCC.

Lenvatinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hypertension: elevated blood pressure requiring monitoring. - Diarrhea: watery stools that may lead to dehydration. - Fatigue: persistent tiredness affecting daily activities. - Decreased appetite: reduced desire to eat, potentially causing weight loss. - Nausea: upset stomach that can be mild to moderate. - Weight loss: unintended loss of body weight.

Serious or Rare Side Effects: - Hepatic failure: severe liver injury requiring immediate medical attention. - Arterial thromboembolism: blood clot formation in arteries. - Severe hemorrhage: uncontrolled bleeding, especially gastrointestinal. - Gastrointestinal perforation or fistula: serious gut wall injury. - Severe infection: opportunistic infections due to immune modulation. - Cardiac dysfunction: heart failure or reduced ejection fraction.

Before initiating therapy, clinicians should evaluate baseline health status and monitor patients regularly.

- Blood pressure monitoring: check and control hypertension throughout treatment. - Liver function assessment: perform baseline and periodic liver enzyme tests. - Proteinuria screening: test urine for protein to detect renal effects. - Anticoagulant review: assess bleeding risk when used with anticoagulants. - Drug interaction check: evaluate concomitant medications for CYP3A4 effects. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Lenvatinib has a potential for pharmacokinetic and pharmacodynamic interactions that may require dose adjustment or avoidance.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase lenvatinib exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): decrease lenvatinib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): raise bleeding risk.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may potentiate blood pressure changes. - Diuretics: can affect electrolyte balance and renal function. - Other anti‑angiogenic agents: additive risk of hypertension and vascular events. - Immunosuppressants (e.g., cyclosporine): possible altered metabolism. - QT‑prolonging drugs: monitor cardiac rhythm for arrhythmias.